The Role of Immunotherapy in Recurrent or Metastatic Cervical Cancer

H&O What makes cervical cancer a good target for immunotherapy? LR Cervical cancer is a good target for immunotherapy because its presence indicates an impairment in […]

Current and Emerging Immunotherapies for Recurrent Cervical Cancer

Abstract: Approximately 4290 women in the United States and 311,000 women worldwide died of cervical cancer in 2021. The management of advanced, recurrent, and/or metastatic cervical […]

Hem/Onc News

Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer On September 20, the US Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak, […]

Hem/Onc News

First Biosimilar to Pegfilgrastim Approved to Decrease Risk for Infection During Cancer Treatment On June 4, the US Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila, […]